Literature DB >> 34027556

Drug-induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms Caused by Lenalidomide: Case Report and Review of the Literature.

Shin-Ichi Osada1, Takahiko Sato.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34027556      PMCID： PMC9367031          DOI： 10.2340/00015555-3835

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  10 in total

1.  A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide.

Authors:  Hamid Shaaban; Trevor Layne; Gunwant Guron
Journal:  J Oncol Pharm Pract       Date:  2013-09-02       Impact factor: 1.809

Review 2.  Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019.

Authors:  Tetsuo Shiohara; Yoshiko Mizukawa
Journal:  Allergol Int       Date:  2019-04-16       Impact factor: 5.836

3.  Drug reaction with eosinophilia and systemic symptoms caused by lenalidomide.

Authors:  Caterina Foti; Annarita Antelmi; Antonio Mazzocca; Francesco Saverio Vella; Paolo Romita; Stefania Pugliese; Daniela Lomazzo; Piero Portincasa; Giuseppe Palasciano
Journal:  Eur J Dermatol       Date:  2012 Nov-Dec       Impact factor: 3.328

4.  Highly Probable Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Associated With Lenalidomide.

Authors:  Anusha Shanbhag; E Ryan Pritchard; Kshitij Chatterjee; Drayton A Hammond
Journal:  Hosp Pharm       Date:  2017-07-18

5.  Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study.

Authors:  S H Kardaun; P Sekula; L Valeyrie-Allanore; Y Liss; C Y Chu; D Creamer; A Sidoroff; L Naldi; M Mockenhaupt; J C Roujeau
Journal:  Br J Dermatol       Date:  2013-11       Impact factor: 9.302

Review 6.  Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking.

Authors:  S A Walsh; D Creamer
Journal:  Clin Exp Dermatol       Date:  2011-01       Impact factor: 3.470

7.  A function for interleukin 2 in Foxp3-expressing regulatory T cells.

Authors:  Jason D Fontenot; Jeffrey P Rasmussen; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2005-10-16       Impact factor: 25.606

8.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

9.  Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease.

Authors:  Yoshiko Mizukawa; Kazuhisa Hirahara; Yoko Kano; Tetsuo Shiohara
Journal:  J Am Acad Dermatol       Date:  2018-09-18       Impact factor: 11.527

10.  The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Authors:  Gang Lu; Richard E Middleton; Huahang Sun; MarkVic Naniong; Christopher J Ott; Constantine S Mitsiades; Kwok-Kin Wong; James E Bradner; William G Kaelin
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.